You bet I do. If America and the EU tighten the economic screws on the Russian Federation you can bet they will flinch. It's all about trade and money involved. Putin has much to give up if he enters a war. He is already one of the richest characters in the world and I can't see him giving that up. Remember Afghanistan (rays) in the early 1980's. I do!
Putin will be run out of Dodge if he commits to military action in Ukraine. What a despot he would become in his own country. He has way to much to lose and he knows it ( and BTW, he is a very smart guy). The Russian people (at least the younger populace) is very wary of Putin and the old Soviet way of thinking. They will stand against him.
For treatment of Essential Thrombocythemia. I'll get the stock price may touch $7.50 today.
Long CLDX and GALE
There are many reasons that I find RNN to be interesting. They have three drug candidates with potential and I would advise you to visit their website for the latest updates. Relating to the drug that is farthest along and other tid-bits:
From: Clin Oncol 15:2403
Though from a small study, data suggests that Archexin has the potential of prolonging survival in advanced pancreatic cancer patients.
Also with regard to Archexin, a phase IIa clinical trial in patients with renal cancer began this month.
Shares were just diluted with a twenty million offering at $1.05 a share.
I'm no expert like Longs_vrts or Don Frankie but I see potential with RNN.
DO YOUR OWN RESEARCH!
I own 11,000 shares with a cost basis of .96 cents
More dirt is pending.
Agreed. If their finances (and mine as a share holder) are that dire eliminate the dividend. Just trying to look on the bright side of things. Watch the share price spike on any lukewarm news as AT is under valued.
It's hard to peg the bottom though and commit to buy more at this juncture.
A very good summary indeed. I agree with most of the points that you cover here. People who buy at this point should do well.
Buy RNN first thing Monday morning.
LONG CLDX, GALE, RNN
Archexin is a unique anti-sense drug candidate that specifically inhibits the cancer cell signaling protein Akt-1. Archexin is the only specific inhibitor of Akt-1 in clinical development. The activated form of Akt-1, which is involved in cancer cell growth, survival, angiogenesis, and drug resistance, has shown to be present or elevated in more than 12 different human cancer cell lines, including pancreatic and renal cell carcinoma. By inhibiting Akt-1, Archexin has shown to both inhibit the growth of human renal cell carcinoma cell lines and exhibit a longer survival benefit in the human renal cell carcinoma animal xenograft model. Thus, while Akt-1 is a very specific anti-cancer target it may have broad therapeutic potential across multiple types of cancer. Archexin has completed a Phase I clinical trial in cancer patients with solid tumors and was shown to be safe and well tolerated. The dose-limiting toxicity was a grade 3 fatigue. In a small Phase IIa trial in advanced pancreatic cancer patients, Archexin in combination with gemcitabine was shown to be safe and well tolerated. It demonstrated a preliminary efficacy signal with a median survival of 9.1 months in evaluable patients.
I to think there is potential with RNN. At $1 share price you are getting 3 drug candidates for .33c each.
After CLDX's pps fell from the 38 level I sold some of my shares @29 and got into GALE @2.08 and RNN@1.03
So now I hold CLDX on profit play and have the diversification of GALE and RNN.
Holding only CLDX in the Biotech space made me nervous.
Good luck to you.
Today's drop of 17% tells it all I'm afraid to say and most likely will happen after the market closes. I do hope that I am wrong.
This investment style is a sure winner. Never goes out of style.....
What? I own 3,900 shares and made my first purchase at $3.86 I am long in AT and was very surprised to see the drop happen today. I won't add any more to my position but will ride out the down draft. Good luck with your investment in AT glee. Sonnyboy signing out.